CS
CASC

Candriam SCA’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Candriam SCA’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-174,500
Closed -$2.87M – 648
2015
Q3 		$2.87M Buy
+174,500
New +$3.58M 0.07% 290
2015
Q2 		– Sell
-123,333
Closed -$1.21M – 681
2015
Q1 		$1.21M Hold
123,333
– – 0.02% 436
2014
Q4 		$1.41M Buy
+123,333
New +$1.34M 0.03% 404

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Candriam SCA's CASC Position: Q4 2015 in Review

Candriam SCA sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2015, closing a stake of 174,500 shares — an estimated $2.87M sold.

Candriam SCA first reported a position in CASC in Q4 2014 and held it in 3 quarters. The position peaked at $2.87M in Q3 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

  • Candriam SCA reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Candriam SCA sold 174,500 Cascadian Therapeutics, Inc. shares in Q4 2015, an estimated $2.87M.
  • Candriam SCA first reported a position in Cascadian Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Candriam SCA's Cascadian Therapeutics, Inc. position peaked at $2.87M in Q3 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on Candriam SCA's 13F filing for Q4 2015, filed 25 Jan 2016.